# Study of KITE-222 in Participants With Relapsed/Refractory Acute Myeloid Leukemia

> **NCT04789408** · PHASE1 · TERMINATED · sponsor: **Kite, A Gilead Company** · enrollment: 15 (actual)

## Conditions studied

- Acute Myeloid Leukemia

## Interventions

- **DRUG:** Cyclophosphamide
- **DRUG:** Fludarabine
- **BIOLOGICAL:** KITE-222

## Key facts

- **NCT ID:** NCT04789408
- **Lead sponsor:** Kite, A Gilead Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-07-19
- **Primary completion:** 2024-05-18
- **Final completion:** 2024-05-18
- **Target enrollment:** 15 (ACTUAL)
- **Why stopped:** Study was terminated due to futility
- **Last updated:** 2025-07-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04789408

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04789408, "Study of KITE-222 in Participants With Relapsed/Refractory Acute Myeloid Leukemia". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT04789408. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*